1Lucas A R,Korol R,Pepine C J.Inflammation in atherosclerosis:some thoughts about acute coronary syndromes[J].Circulation,2006,113(17):e728-e732.
2Jemaa R,Rojbani H,Kallel A,et al.Association between the-2518G/A polymorphism in the monocyte chemoattractant protein-1(MCP-1)gene and myocardial infarction in Tunisan patients[J].Clin Chim Acta,2008,390(1-2):122 125.
3Leonad E J,Yoshimura T.Human monocyte chemoatractant protein-1(MCP-1)[J].Imunol Today,1990,11:97-101.
4Beall C J,Mahajan S,Kalattukudy P E.Conversion of monocyte cheoattractant protein-1 into a neutrophil attractant by substitution of two Aminoa acids[J].Biol Chem,1992,267:2459-3455.
5Biswas S K,Sodhi A.Tyrosine phosphorylation-mediated signal trans-duction in MCP-1-induced macrophage activation:role for receptor dimerization,focal adhesion protein complex and JAK/STAT pathway[J].Int Immunopharmacol,2002,2(8):1095-1107.
6Jiang Y,Beller D I,Frendi G,et al.Monocyte chemoattracctant protein 1-regulates adhesion molecule expression and cytokine production in human monocytes[J].Immunol,1992,148:2423-2428.
7James A L,David A M,Marc S S,et al.Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndrome[J].Circulation,2003,107:690-695.
8Shah P K.Pathophysiology of plaque rupture and the concept of plaque stablization[J].Canliol Clin,2003,21:303-314.
9Hellstrom H R.Multiple plaque rupture in acute coronary syndromes[J].Circulation,2003,107(9):41-64.
10Quilici J,Gallo R.Physiopathology of acute coronary syndromes[J].Ann Cardiol Angeiol(Paris),1999,48(9-10):611-623.
二级参考文献23
1Usui H, Shikata K, Matsuda M, et al, HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats.Nephrol Dial Transplant,2003,18:265-272.
2Ota T, Takamura T, Ando H, et al. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia, 2003, 46: 843-851.
3Chow F, Ozols E, Nikolic-Paterson DJ, et al. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int, 2004, 65: 116-128.
4Chow FY, Nikolic-Paterson DJ, Ozols E, et al. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kindney Int, 2006,69:73-80.
5Gu L, Hagiwara S, Fan Q, et al. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant, 2006,21:299-313.
6Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocytes activation in the pathogenesis of diabetic nephropathy. Am J Pathol, 2003, 162:1123-1137.
7Mundel P, Reiser J, Kriz W. Induction of differentiation in cultured rat and human podocytes. J Am Soc Nephrol, 1997,8:697-705.
8Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease. podocyte injury comes of age in diabetic nephropathy. Diabetes, 2005,54:1626-1634.
9Huber TB, Reinhardt HC, Exner M, et al. Expression of functional CCR and CXCR chemokine receptors in podocytes. J Immunol, 2002, 168: 6244-6252.
10Reiser J, von Gersdorff G, Loos M, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest, 2004, 113:1390-1397.
同被引文献12
1Dziegiel P,Jelen M,Muszczynska B. Role of metallothionein expression in non-small cell lung carcinomas[J].{H}Roczniki Akademii Medycznej W Bialymstoku,2004,(Suppl 1):43-45.
2Mendez-Armenta M,Villeda-Hernandez J,Barroso-Moguel R. Brain regional lipid peroxidation and metallothionein levels of developing rats exposed to cadmium and dexamethasone[J].{H}Toxicology Letters,2003,(02):151-157.
3Krzeslak A,Forma E,Jozwiak P. Metallothionein 2A genetic polymorphisms and risk of ductal breast cancer[J].{H}Clinical and Experimental Medicine,2012.
4Luo G,Zheng L,Zhang X. Genotyping of single nucleotide polymorphisms using base-quenched probe:a method does not invariably depend on the deoxyguanosine nucleotide[J].{H}Analytical Biochemistry,2009,(02):161-166.
5Steinmetz OM,Panzer U,Harendza S. No association of the-2518 MCP-1 A/G promoter polymorphism with incidence and clinical course of IgA nephropathy[J].{H}Nephrology Dialysis Transplantation,2004,(03):596-601.
6Gruber HE,Hoelscher G,Ingram JA. 1,25(OH) 2-vitamin D3 inhibits proliferation and decreases production of monocyte chemoattractant protein-1,thrombopoietin,VEGF,and angiogenin by human annulus cells in vitro[J].Spine (Phila Pa 1976),2008,(07):755-765.
7Karrer S,Bosserhoff AK,Weiderer P. The-2518 promotor polymorphism in the MCP-1 gene is associated with systemic sclerosis[J].{H}Journal of Investigative Dermatology,2005,(01):92-98.
8Szalai C,Duba J,Prohaszka Z. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD).Coincidence of elevated Lp(a) and MCP-1-2518 G/G genotype in CAD patients[J].{H}ATHEROSCLEROSIS,2001,(01):233-239.
9Simeoni E,Winkelmann BR,Hoffmann MM. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis[J].{H}EUROPEAN HEART JOURNAL,2004,(16):1438-1446.
10Giacconi R,Cipriano C,Muti E. Novel-209A/G MT2A polymorphism in old patients with type 2 diabetes and atherosclerosis:relationship with inflammation (IL-6) and zinc[J].{H}BIOGERONTOLOGY,2005,(06):407-413.
